XML 30 R32.htm IDEA: XBRL DOCUMENT v3.2.0.727
Supplemental Financial Information (Details) - USD ($)
shares in Millions, $ in Millions
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 27, 2015
Apr. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
Supplemental Financial Information                
Earnings from continuing operations allocated to common shares     $ 783.0   $ 423.0 $ 1,309.0 $ 646.0  
Net earnings allocated to common shares     780.0   $ 463.0 3,061.0 837.0  
Noncash impact of tax benefits from resolution of prior year tax positions included in other, net use of cash in Net cash from operating activities             70.0  
Component of long-term investment                
Short-term Investments, Total     7,129.0     7,129.0   $ 397.0
Investments     243.0     243.0   229.0
Gain on sale of Mylan shares     $ 207.0     207.0    
Pretax gain on sale of discontinued operations           2,820.0    
Decrease in fair value of contingent consideration           79.0    
Proceeds from Divestiture of Businesses           230.0    
Debt and Lines of Credit                
Long-term debt issued       $ 2,500.0        
Post-employment Obligations and Other Long-term Liabilities:                
Non-cash impact of tax expense associated with the gain on the sale of businesses           $ 1,100.0    
Mylan NV                
Component of long-term investment                
Number of shares owned     69.7     69.7    
Percentage of shares held before sale of generics pharmaceuticals business to Mylan Inc           22.00%    
Ownership interest (as a percent)     14.00%     14.00%    
Mylan                
Component of long-term investment                
Proceeds from Divestiture of Businesses   $ 40.3            
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc   110.0            
Interest rate swaps                
Debt and Lines of Credit                
Notional amount of contracts entered during the period       2,500.0        
2.00% Senior Notes Due March 15, 2020                
Debt and Lines of Credit                
Long-term debt issued       $ 750.0        
Interest rate percentage       2.00%        
2.55% Senior Notes Due March 15, 2022                
Debt and Lines of Credit                
Long-term debt issued       $ 750.0        
Interest rate percentage       2.55%        
2.95% Senior Notes Due March 15, 2025                
Debt and Lines of Credit                
Long-term debt issued       $ 1,000.0        
Interest rate percentage       2.95%        
Defined Benefit Plans                
Post-employment Obligations and Other Long-term Liabilities:                
Company contributions           $ 547.0 330.0  
Medical and Dental Plans                
Post-employment Obligations and Other Long-term Liabilities:                
Company contributions           24.0 $ 40.0  
Equity securities                
Component of long-term investment                
Short-term Investments, Total     $ 4,672.0     4,672.0    
Investments     226.0     226.0   212.0
Other,                
Component of long-term investment                
Investments     17.0     17.0   17.0
Other, Primarily Bank Time Deposits and Us Treasury Bills Member                
Component of long-term investment                
Short-term Investments, Total     $ 2,457.0     2,457.0   $ 397.0
Developed markets branded generics pharmaceuticals business | Mylan                
Component of long-term investment                
Gain on sale of Mylan shares           207.0    
Proceeds from Divestiture of Businesses           $ 40.3    
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc 110.0         110.0